In August 2025, Livewire featured Minotaur Capital's approach to investing in the weight-loss pharmaceutical market. Our fund's strategy involves a three-pronged trade: long positions in Eli Lilly and Chugai Pharmaceutical, with a short position on Novo Nordisk.
The article highlighted how our AI system, Taurient, uncovered a promising investment in Chugai Pharmaceutical:
"Chugai, a Japanese pharma company best known for oncology, was flagged by our proprietary AI system, Taurient. It appeared in an article written in Japanese characters and revealed the company's increasing focus on mid-sized molecule drug discovery," Armina Rosenberg wrote.
This discovery led us to identify Chugai's underappreciated obesity pipeline, including orforglipron, an oral GLP-1 now licenced to Eli Lilly, and GYM329, a potential companion drug addressing muscle loss in GLP-1 treatments.
The piece also examined our perspective on the GLP-1 market:
"We're long Eli Lilly and short Novo – a relative value expression on the same megatrend. In our view, Lilly is winning the battle on all fronts – product, pipeline, and pricing," Rosenberg penned.
The piece underscored Minotaur Capital's approach to the weight-loss pharmaceutical sector, highlighting our ability to identify opportunities beyond obvious market leaders and leverage AI for comprehensive market research.